PLX (Protalix BioTherapeutics Inc. (DE)) stock: $2.69, $216.7M market cap, $27.4M cash, $189.3M EV, $244.6M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Pipeline assets
Elelyso
Approved · Active Modality: recombinant enzyme replacement therapy (plant cell-expressed)
Aliases taliglucerase alfa
Target glucocerebrosidase (acid beta-glucosidase)
Partnerships Global rights to market/sell licensed to Pfizer ex-Brazil (drug substance supplied by company through 2030); Brazil commercialization via Fiocruz/BioManguinhos (therapy of choice for newly diagnosed Gaucher patients per Brazilian MoH guidelines).
Indications- Gaucher disease (adults and children ≥4 years) (Approved)
Status note Plant cell-expressed recombinant glucocerebrosidase approved in the U.S., Brazil, Israel and other jurisdictions for Gaucher disease. Company holds worldwide rights outside the Pfizer (global ex-Brazil) and Fiocruz (Brazil) arrangements.
Elfabrio
Approved · Active Modality: recombinant enzyme replacement therapy (PEGylated)
Aliases PRX-102, pegunigalsidase alfa-iwxj
Target alpha-galactosidase A (GLA)
Partnerships Commercialized worldwide by Chiesi Farmaceutici under exclusive U.S. and ex-U.S. license/supply agreements; company supplies drug product and receives 15-40% of net sales. $25M milestone received Mar 31, 2026 following EU E4W approval; up to $740M (U.S.) and $270M (ex-U.S.) additional milestones. Kwang Dong Pharm. is Chiesi's distributor/MOH-holder in South Korea.
Indications- Fabry disease (adults) (Approved)
Status note PEGylated recombinant human alpha-galactosidase A for Fabry disease; approved in the U.S. (with a boxed warning) and EU. Mar 2026 EU approval of a 2 mg/kg every-4-weeks (E4W) dosage in addition to the 1 mg/kg every-2-weeks dosage; South Korea orphan marketing authorization granted May 2026. U.S. Patent No. 9,194,011 term extended to Nov 17, 2035.
PRX-119
Preclinical · Active Modality: PEGylated recombinant human DNase I (plant cell-expressed)
Target extracellular DNA (NETs)
Partnerships Company holds worldwide commercialization rights.
Indications- NETs-related diseases (neutrophil extracellular traps) (Preclinical)
Status note Plant cell-expressed PEGylated recombinant human DNase I candidate for long and customized systemic circulation for NETs-related diseases. Early-stage; company turning focus to new early-stage candidates in indications with high unmet need, including renal diseases.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.